Valbiotis SA (FR:ALVAL) has released an update.
Valbiotis, a French scientific research laboratory, has reported its latest share capital and voting rights information, highlighting a total of 15,794,596 shares and 16,435,558 exercisable voting rights as of August 31, 2024. The company is known for developing food supplements aimed at preventing metabolic disorders related to cardiovascular diseases and plans to market its products both internationally through licensing agreements and directly in France. Valbiotis, established in 2014 and supported by significant financial backing from European funds, is also part of the PEA-PME scheme.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.